PCSK9 and atherosclerosis: In ACC 2017, a large-scale clinical study called Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) trial was published, which focused on the effect of PCSK9 inhibitor to atherosclerosis.